


## Denmark

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline		2009		2012		2015		2018
International units	Factor VIII	0.00	<b>A</b>	6.18	•	0.00		0.00
per capita	Factor IX	0.00	<b>A</b>	1.25	•	0.00		0.00
Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes	•	No		No
	National Haemophilia Council or Co-ordinating Group	No		No		No		No
	Number of groups in decision-making on haemophilia care	0	<b>A</b>	2	<b>A</b>	3		3
	Number of groups choosing haemophilia treatment products	0	<b>A</b>	3		3		3
	National Tender for procurement of factor concentrates			No	<b>A</b>	Yes		Yes
Treatment	Home Treatment	Yes		Yes		Yes		Yes
regimens	% of people with haemophilia using home treatment			51-75%	<b>A</b>	76-100%		76-100%
	Treatment delivered to the patient's home	Some		Some		Some		Unknown
	Prophylaxis treatment availability	Yes		Yes	•	Some	<b>A</b>	Yes
	Children currently on prophy (%)	76-100%		76-100%		76-100%		76-100%
	Adults currently on prophy (%)	1-25%	<b>A</b>	26-50%				51-75%
	Access to ITI (% of people with inhibitors)	100%		100%		100%		100%
Access to	Emergency medicine and acute surgery			Sometimes	<b>A</b>	Yes	•	Sometimes
specialist services	Paediatrics			Yes		Yes		Yes
	Infectious disease specialists (especially HIV)			Sometimes	<b>A</b>	Yes		Yes
	Hepatology			Yes		Yes		Yes
	Rheumatology			Sometimes	<b>A</b>	Yes		Yes
	Orthopaedics			Yes		Yes		Yes
	Physiotherapy			Sometimes	<b>A</b>	Yes		Yes
	Dentistry			Sometimes	<b>A</b>	Yes	•	Sometimes
	Obstetrics and Gynaecology					Yes	•	Sometimes
	Genetics			Yes		Yes		Yes
	Social and psychological support			Sometimes				Sometimes
	Pain management			Sometimes	<b>A</b>	Yes	•	Sometimes
	General surgery			Yes		Yes	•	Sometimes
	Urology			Yes		Yes	•	Sometimes
Share of Expected	Haemophilia A	65%	<b>A</b>	69%	•	68%	_	67%
Bleeding Disorder	Haemophilia B	54%	<b>A</b>	55%	▼	54%	<b>A</b>	58%
Prevalence	von Willebrand Disease			7%	•	7%	▼	5%
Haemophilia	Pasma-derived factor concentrate	Rarely		Rarely		Rarely		Rarely
replacement	Recombinant factor concentrate	Always		Always		Always		Always
therapy	Plasma	Never		Never		Never		Never
	Cryoprecipitate	Never		Never		Never		Never
VWD replacement	Plasma-derived factor concentrate			Always		Always		Always
therapy	DDAVP			Always		Always		Always
	Plasma			Never		Never		Never
	Cryoprecipitate			Never				Never